
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8710979/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Suv39h-Mediated Histone H3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin. Current Biology, 2003, 13, 1192-1200.	1.8	1,090
2	Establishment and Maintenance of Genomic Methylation Patterns in Mouse Embryonic Stem Cells by Dnmt3a and Dnmt3b. Molecular and Cellular Biology, 2003, 23, 5594-5605.	1.1	652
3	Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nature Genetics, 2007, 39, 391-396.	9.4	308
4	A Novel Dnmt3a Isoform Produced from an Alternative Promoter Localizes to Euchromatin and Its Expression Correlates with Activede Novo Methylation. Journal of Biological Chemistry, 2002, 277, 38746-38754.	1.6	302
5	Inactivation of Dnmt3b in Mouse Embryonic Fibroblasts Results in DNA Hypomethylation, Chromosomal Instability, and Spontaneous Immortalization. Journal of Biological Chemistry, 2005, 280, 17986-17991.	1.6	237
6	Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology, 2000, 31, 488-495.	3.6	230
7	Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development (Cambridge), 2006, 133, 1183-1192.	1.2	150
8	New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene, 1999, 18, 4993-4998.	2.6	138
9	Anti-viral protein APOBEC3G is induced by interferon- $\hat{l}\pm$ stimulation in human hepatocytes. Biochemical and Biophysical Research Communications, 2006, 341, 314-319.	1.0	127
10	Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. International Journal of Cancer, 2007, 120, 469-476.	2.3	117
11	Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing. PLoS ONE, 2011, 6, e24907.	1.1	86
12	Organâ€specific profiles of genetic changes in cancers caused by activationâ€induced cytidine deaminase expression. International Journal of Cancer, 2008, 123, 2735-2740.	2.3	80
13	Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing. PLoS ONE, 2012, 7, e35052.	1.1	76
14	Risk Factors for Recurrence of Primary Sclerosing Cholangitis after Living Donor Liver Transplantation in Japanese Registry. American Journal of Transplantation, 2011, 11, 518-527.	2.6	72
15	Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplantation, 2000, 25, 105-108.	1.3	71
16	Impact of Donor Age on Recipient Survival in Adult-to-Adult Living-donor Liver Transplantation. Annals of Surgery, 2018, 267, 1126-1133.	2.1	63
17	Risk Factors for Recurrence of Primary Sclerosing Cholangitis After Living Donor Liver Transplantation: A Single Center Experience. Digestive Diseases and Sciences, 2009, 54, 1347-1354.	1.1	55
18	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. Journal of Gastroenterology, 2012, 47, 444-451.	2.3	46

#	Article	IF	CITATIONS
19	Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. International Journal of Cancer, 2012, 130, 1294-1301.	2.3	37
20	Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after livingâ€donor liver transplantation. Hepatology Research, 2013, 43, 67-71.	1.8	37
21	<i>TERT</i> promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver diseaseâ€related hepatocellular carcinoma. International Journal of Cancer, 2016, 139, 2512-2518.	2.3	36
22	Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein. Oncogene, 2000, 19, 827-830.	2.6	34
23	Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. Journal of Gastroenterology, 2009, 44, 359-364.	2.3	32
24	Wnt/?-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts. International Journal of Cancer, 2002, 99, 681-688.	2.3	31
25	Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience. Transplantation Direct, 2017, 3, e334.	0.8	30
26	<i>De novo</i> activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antiviral Therapy, 2011, 16, 479-487.	0.6	29
27	Treatment with sofosbuvir and ledipasvir without ribavirin for 12Âweeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. Journal of Gastroenterology, 2017, 52, 986-991.	2.3	28
28	Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. Journal of Gastroenterology, 2001, 36, 633-636.	2.3	27
29	Expression of APOBEC2 is transcriptionally regulated by NF-κB in human hepatocytes. FEBS Letters, 2006, 580, 731-735.	1.3	27
30	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochemical Journal, 2001, 356, 859-866.	1.7	26
31	Significance of pretransplant abstinence on harmful alcohol relapse after liver transplantation for alcoholic cirrhosis in <scp>J</scp> apan. Hepatology Research, 2014, 44, E428-36.	1.8	23
32	p73β, a Variant of p73, Enhances Wnt/β-Catenin Signaling in Saos-2 Cells. Biochemical and Biophysical Research Communications, 2001, 283, 327-333.	1.0	22
33	Individualized Extension of Pegylated Interferon Plus Ribavirin Therapy for Recurrent Hepatitis C Genotype 1b After Living-Donor Liver Transplantation. Transplantation, 2010, 90, 661-665.	0.5	22
34	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. Digestion, 2011, 84, 43-49.	1.2	22
35	Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. Journal of Hepatology, 2014, 61, 492-501.	1.8	22
36	Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers, 2019, 11, 405.	1.7	22

#	Article	IF	CITATIONS
37	Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion, 2017, 96, 228-230.	1.2	21
38	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
39	Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Scientific Reports, 2017, 7, 45605.	1.6	20
40	Sonazoid-enhanced ultrasonography guidance improves the quality of pathological diagnosis in the biopsy of focal hepatic lesions. European Journal of Gastroenterology and Hepatology, 2016, 28, 1462-1467.	0.8	19
41	Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation. Transplantation, 2008, 85, 855-862.	0.5	18
42	Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12Âweeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. Journal of Gastroenterology, 2019, 54, 660-666.	2.3	16
43	A Functioning Black Adenoma of the Adrenal Gland Internal Medicine, 1997, 36, 398-402.	0.3	15
44	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochemical Journal, 2001, 356, 859.	1.7	15
45	Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transplantation, 2008, 14, 1044-1047.	1.3	15
46	Multiregional wholeâ€genome sequencing of hepatocellular carcinoma with noduleâ€inâ€nodule appearance reveals stepwise cancer evolution. Journal of Pathology, 2020, 252, 398-410.	2.1	15
47	Dynamics of Defective Hepatitis C Virus Clones in Reinfected Liver Grafts in Liver Transplant Recipients: Ultradeep Sequencing Analysis. Journal of Clinical Microbiology, 2013, 51, 3645-3652.	1.8	14
48	Hepatitis B virus genotype E infection among Egyptian health care workers. Journal of Translational Internal Medicine, 2017, 5, 100-105.	1.0	14
49	Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Scientific Reports, 2018, 8, 18070.	1.6	14
50	Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome. Scientific Reports, 2020, 10, 2651.	1.6	14
51	Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transplant International, 2016, 29, 119-121.	0.8	12
52	Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatology Research, 2016, 46, 541-551.	1.8	12
53	Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. Clinical Transplantation, 2017, 31, e13109.	0.8	12
54	Simultaneous Occurrence of Inflammatory Bowel Disease and Myelodysplastic Syndrome due to Chromosomal Abnormalities in Bone Marrow Cells. Digestion, 2009, 79, 215-219.	1.2	11

#	Article	IF	CITATIONS
55	Spontaneous Rupture of Liver Plasmacytoma Mimicking Hepatocellular Carcinoma. Internal Medicine, 2010, 49, 653-657.	0.3	11
56	Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1747-1756.	1.2	11
57	Exploring the hepatitis C virus genome using single molecule real-time sequencing. World Journal of Gastroenterology, 2019, 25, 4661-4672.	1.4	11
58	Islet-cell hyperplasia causing hyperinsulinemic hypoglycemia in an adult. Journal of Gastroenterology, 1998, 33, 125-128.	2.3	10
59	Chronic Rejection Associated with Antiviral Therapy for Recurrent Hepatitis C after Living-Donor Liver Transplantation. Transplantation, 2014, 97, 344-350.	0.5	10
60	Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatology Research, 2015, 45, 1360-1362.	1.8	9
61	Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation, 2016, 100, 54-60.	0.5	9
62	The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of antiâ€ <scp>HB</scp> c–positive livers. Pediatric Transplantation, 2018, 22, e13227.	0.5	9
63	Colonic Polyposis Associated With Autoimmune Pancreatitis. Pancreas, 2009, 38, 840-842.	0.5	8
64	Frequent overlap of active hepatitis in recurrent primary sclerosing cholangitis after living-donor liver transplantation relates to its rapidly progressive course. Human Pathology, 2011, 42, 1329-1336.	1.1	8
65	Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation. Transplant International, 2015, 28, 251-252.	0.8	8
66	Helicobacter pylori in solid-organ transplant recipient. Current Opinion in Organ Transplantation, 2008, 13, 586-591.	0.8	7
67	Successful Telaprevir Treatment in Combination of Cyclosporine against Recurrence of Hepatitis C in the Japanese Liver Transplant Patients. Biological and Pharmaceutical Bulletin, 2014, 37, 417-423.	0.6	7
68	Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after livingâ€donor liver transplantation: A Japanese multicenter experience. Hepatology Research, 2016, 46, 1285-1293.	1.8	7
69	DNA methyltransferase 3B plays a protective role against hepatocarcinogenesis caused by chronic inflammation via maintaining mitochondrial homeostasis. Scientific Reports, 2020, 10, 21268.	1.6	7
70	Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization. Cancer Research, 2022, 82, 1712-1723.	0.4	7
71	Overproduced p73α activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Letters, 2001, 509, 47-52.	1.3	6
72	Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. Journal of Viral Hepatitis, 2009, 17, 481-7.	1.0	6

#	Article	IF	CITATIONS
73	Generalized morphea with preceding severe pain and coexistent early primary biliary cirrhosis. European Journal of Dermatology, 2015, 25, 365-366.	0.3	6
74	Association of Macâ€2â€binding protein glycosylation isomer level with nutritional status in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1649-1658.	1.4	6
75	Successful endoscopic removal of fractured guidewire fragments from a peripheral bile duct using a biliary stent delivery system and biopsy forceps. Endoscopy, 2018, 50, E279-E280.	1.0	6
76	Utility of ultrasoundâ€guided liver tumor biopsy for nextâ€generation sequencingâ€based clinical sequencing. Hepatology Research, 2019, 49, 579-589.	1.8	6
77	Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus. Carcinogenesis, 2021, 42, 672-684.	1.3	6
78	Use of Nakanuma staging and cytokeratinÂ7 staining for diagnosing recurrent primary biliary cholangitis after livingâ€donor liver transplantation. Hepatology Research, 2020, 50, 478-487.	1.8	5
79	Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 246-250.	0.4	5
80	RelA suppresses the Wnt/β-catenin pathway without exerting trans-acting transcriptional ability. International Journal of Molecular Medicine, 2002, 9, 489.	1.8	4
81	Effect of maintenance therapy with lowâ€dose peginterferon for recurrent hepatitis C after living donor liver transplantation. Journal of Viral Hepatitis, 2012, 19, 32-38.	1.0	4
82	Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis <scp>C</scp> after living donor liver transplantation. Hepatology Research, 2014, 44, E279-83.	1.8	4
83	Lateâ€onset acetaminophenâ€induced allergic hepatitis with progression to chronicity. Hepatology Research, 2015, 45, 814-817.	1.8	4
84	Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases. Surgical Case Reports, 2015, 1, 124.	0.2	3
85	Ultrasoundâ€guided microfoam sclerotherapy with polidocanol for symptomatic giant hepatic cyst: Initial experience. Hepatology Research, 2018, 48, 1055-1063.	1.8	3
86	New sequencing technology, thirdâ€generation nanopore sequencing, for hepatitis C virus research. Hepatology Research, 2019, 49, 961-963.	1.8	3
87	Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis. Internal Medicine, 2019, 58, 67-71.	0.3	3
88	Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Scientific Reports, 2022, 12, 7083.	1.6	3
89	Diverse p53 gene aberration in hepatocellular carcinoma detected by dual-color fluorescence in situ hybridization. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1066-1073.	1.4	2
90	Effective treatment for <i>de novo</i> hepatitis B with nucleotide analogue in patients with hematological malignancies. American Journal of Hematology, 2009, 84, 315-316.	2.0	2

#	Article	IF	CITATIONS
91	Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCG) disease. Acta Hepatologica Japonica, 2017, 58, 406-414.	0.0	2
92	Allograft liver failure awaiting liver transplantation in Japan. Journal of Gastroenterology, 2022, 57, 495-504.	2.3	2
93	<i>De novo</i> hepatitis B virus infection in hepatocellular carcinoma following eradication of hepatitis C virus by interferon therapy. Hepatology Research, 2010, 40, 661-665.	1.8	1
94	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. PLoS ONE, 2013, 8, e58380.	1.1	1
95	Hepatobiliary and Pancreatic: Granulomatous hepatitis due to disseminated bacillus Calmette-Guérin disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1538-1538.	1.4	1
96	Hepatitis-associated Aplastic Anemia with Rapid Progression of Liver Fibrosis Due to Repeated Hepatitis. Internal Medicine, 2020, 59, 1035-1040.	0.3	1
97	Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. Clinical Journal of Gastroenterology, 2021, 14, 293-296.	0.4	1
98	Beta-catenin-activated hepatocellular adenoma in a male. Clinical Journal of Gastroenterology, 2021, 14, 831-835.	0.4	1
99	Acidâ€ŧreated highâ€amylose corn starch suppresses highâ€fat dietâ€induced steatosis. Journal of Food Science, 2022, , .	1.5	1
100	Gastrointestinal: Ileal ulcers induced by non-steroidal anti-inflammatory drugs. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1346-1346.	1.4	0
101	Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up. Internal Medicine, 2015, 54, 1505-1508.	0.3	0
102	The role of hepatologists in liver transplantation; the results of questionnaire survey for institutions belonging to the Japanese Liver Transplantation Society. Acta Hepatologica Japonica, 2017, 58, 97-104.	0.0	0
103	Jejunal variceal rupture in a patient with myelofibrosis: a case report. Clinical Journal of Gastroenterology, 2021, 14, 542-545.	0.4	0